AbbVie Inc. EV/Operating CF

EV/Operating CF of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/Operating CF growth rates and interactive chart. A valuation metric that measures the enterprise value of a company compared to its operating cash flow. Operating cash flow (OCF) is the amount of cash generated by a company's normal business operations. It can be different from reported net income due to accrual accounting, that is expenses and revenues are recognized differently than cash is received. The cash going in and out of the business is what ultimately determines its financial health, so it's one of the most important metrics to watch. A low EV/OCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/OCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.


Highlights and Quick Summary

Current EV/Operating CF of AbbVie Inc. is 15.22 (as of December 30, 2020)
  • EV/Operating CF for the quarter ending June 29, 2021 was 13.34 (a -6.89% decrease compared to previous quarter)
  • Year-over-year quarterly EV/Operating CF decreased by -8.76%
  • Annual EV/Operating CF for 2020 was 15.22 (a 28.41% increase from previous year)
  • Annual EV/Operating CF for 2019 was 11.85 (a -8.7% decrease from previous year)
  • Annual EV/Operating CF for 2018 was 12.98 (a -29.97% decrease from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/Operating CF of AbbVie Inc.

Most recent EV/Operating CFof ABBV including historical data for past 10 years.

Interactive Chart of EV/Operating CF of AbbVie Inc.

AbbVie Inc. EV/Operating CF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 13.34 14.33
2020 15.22 14.62 16.5 9.82 15.22
2019 11.85 10.41 10.48 10.98 11.85
2018 12.98 13.89 15.78 16.5 12.98
2017 18.54 19.36 20.52 19.21 18.54
2016 18.7 17.73 15.97 14.31 18.7
2015 15.86 22.58 28.47 22.33 15.86
2014 31.27 17.98 17.54 15.3 31.27
2013 14.16 12.8 11.24 12.27 14.16
2012 9.94 9.94 9.94 9.94 9.94
2011 9.94 9.94 9.94 9.94 9.94
2010 9.94

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.